Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTAÂ® (tapentadol), NUCYNTAÂ® ER (tapentadol) extended release tablets and NUCYNTAÂ® (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 bill